Ruhr University Bochum

Good News--MS Drugs Taken While Breastfeeding May Not Affect Child Development

Retrieved on: 
Tuesday, March 5, 2024
NMOSD, Social media, Hellwig, Nervous system, Alzheimer's disease, MD, Ofatumumab, Stroke, German, Pregnancy, Life, Risk, Annual general meeting, Multiple sclerosis, DSM-IV codes, AAN, Health, Migraine, Parkinson's disease, Hypoesthesia, Fatigue, Ruhr University Bochum, Mother, Paresthesia, Infant, Concussion, Spinal cord, Breast milk, Epilepsy, Sclerosis, Disease, Child, Rituximab, Natalizumab, Optic nerve, Brain, Demyelinating disease, Research, Immune system, American Academy, Birth control

MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.

Key Points: 
  • MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.
  • For the study, researchers used the German MS and Pregnancy Registry to identify 183 infants born to mothers taking monoclonal antibodies while breastfeeding.
  • The first exposures to the medications through breastfeeding ranged from the day a child was born to the ninth month of life.
  • After comparing infants exposed to the medications to infants not exposed, researchers found no differences in their health or development.

EQS-News: STRABAG SE: new record output volume, EBIT margin expected to approach 5%

Retrieved on: 
Thursday, February 15, 2024
Acquisition, International, STRABAG, Construction, Climate, Investment, Transport, Growth, Ruhr University Bochum, Policy, Masaryk, FTE, Environment, Renewable energy

The STRABAG SE Group increased its output volume by 8% to € 19.1 billion in the 2023 financial year, setting a new record for this figure.

Key Points: 
  • The STRABAG SE Group increased its output volume by 8% to € 19.1 billion in the 2023 financial year, setting a new record for this figure.
  • In the Czech Republic, output declined, as expected, after a selective approach was taken in response to increased competition in transportation infrastructures.
  • The EBIT margin for the 2023 financial year is expected to approach 5% (2022: 4.2%), higher than originally forecast.
  • “Buoyed by last year’s strong performance, we expect to be able to confirm our record output in 2024.

BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer

Retrieved on: 
Wednesday, January 24, 2024
Health, Technology, Other Science, Research, Artificial Intelligence, Science, Pharmaceutical, Development, Patient, BAI, Euronext Amsterdam, Executive Committee, MD, Culture, Artificial intelligence, Benevolence, AI, Ruhr University Bochum, Drug discovery, Doctor of Philosophy, LEO, Leo Pharma, EVP, Platform, Growth, Medical device

BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the appointment of Dr. Joerg Moeller as Chief Executive Officer and Executive Board member with immediate effect.

Key Points: 
  • BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the appointment of Dr. Joerg Moeller as Chief Executive Officer and Executive Board member with immediate effect.
  • Dr. Joerg Moeller, MD, PhD, brings a wealth of experience to BenevolentAI.
  • Dr. François Nader, Chair of BenevolentAI, commented: “Along with the rest of the Board, I am delighted to welcome Joerg.
  • With his track record of delivering growth through driving performance, I am confident that Joerg will leverage our proprietary and validated Benevolent Platform™ to deliver our patient-centric revenue generating strategy.”
    Dr. Joerg Moeller, Chief Executive Officer of BenevolentAI, commented: “I am excited by the opportunity to lead BenevolentAI.

Myocene signs contract with OGC Nice for muscle fatigue measurement technology

Retrieved on: 
Tuesday, November 21, 2023
School, Injury, Partnership, Ruhr University Bochum, Football, University, Muscle fatigue, Health, Fatigue, Outline of health sciences, Basketball, Rest, Perception, Jean Monnet University, RC Strasbourg Alsace, Muscle contraction, S.C. Braga, HES-SO, Volleyball, CEP, US Ivry, OGC Nice

LIÈGE, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Myocene, the company developing a cutting-edge device for measuring muscle fatigue1, today announces that it has signed a contract to supply its patented technology to the French professional football club OGC Nice. The financial terms of the agreement have not been disclosed.

Key Points: 
  • The top-flight club in France’s Ligue 1 will use Myocene’s technology during training sessions and matches to optimize players' performance.
  • Muscle fatigue measurements will be taken each week throughout the season to assess players’ recovery levels, and their general condition after each match.
  • “We chose Myocene’s device as a tool that allows us to reliably assess the players' 'freshness' and recovery levels,” explained Laurent Bessiere, performance director at OGC Nice.
  • Myocene’s innovative technology can calculate an individual’s exact muscle fatigue index in just two minutes.

Aeva Appoints Dr. Stefan Sommer, Former CEO of ZF Group and Board Member at Volkswagen Group, to its Board of Directors

Retrieved on: 
Tuesday, November 7, 2023
Technology, Alternative Vehicles, Fuels, EV, Electric Vehicles, Automotive, Vehicle Technology, Audio, Video, Hardware, Autonomous Driving, Vehicles, Artificial Intelligence, Aeva Maurelle, NYSE, Continental Group of Institutes, ZF, Organization, FMCW, Original equipment manufacturer, Multimedia, Ruhr University Bochum, Growth, Component, Supervisory board, Chief technology officer, Wolfsburg, Safety, Automation, Perception, Volkswagen, Mechanical engineering, Management

Aeva ® (NYSE: AEVA), a leader in next-generation sensing and perception systems, today announced the appointment of Stefan Sommer to its Board of Directors, effective November 15, 2023.

Key Points: 
  • Aeva ® (NYSE: AEVA), a leader in next-generation sensing and perception systems, today announced the appointment of Stefan Sommer to its Board of Directors, effective November 15, 2023.
  • Dr. Sommer studied Mechanical Engineering and earned his Engineering Doctorate from Ruhr University Bochum.
  • “The automotive industry is undergoing profound technological change where innovation will be driven through partnerships with advanced technology solution providers,” said Dr. Sommer.
  • I look forward to bringing my experience to bear for Aeva as we bring this next-generation sensing and perception technology to market.”

Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer

Retrieved on: 
Tuesday, September 12, 2023
Oxidative phosphorylation, Pancreatic cancer, NF, University, Cell death, GAPDH, Glomus tumor, ATP, Enzyme, Agonal respiration, Quality of life, Cancer, Research, Ruhr University Bochum, Molecular medicine, University of Duisburg-Essen, Patient, Manuscript, Apoptosis, Organ (biology), Journal of Cellular and Molecular Medicine, ST, Factorization of polynomials, Pharmaceutical industry, Panaveli

BERWYN, PA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the outcomes and quality of life for patients, today announced publication of positive data in the peer-reviewed Journal of Cellular and Molecular Medicine in a manuscript titled, “GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells1.” The publication by Majchrzak-Stiller, et al. (2023) details the multiple sites of action of GP-2250 in the disruption of energy production of cancer cells and the downregulation of tumor promoting transcription factors.

Key Points: 
  • GP-2250 is a highly selective yet broadly active cancer therapeutic with a unique mechanism of action that suppresses cancer by disrupting its energy metabolism, leading to cancer cell death through several validated mechanisms.
  • GP-2250 is currently being studied in a Phase 1 clinical trial for pancreatic cancer.
  • Results of the preclinical study showed that at the lowest dose of GP-2250 tested (250 μM), a significant decrease in ATP was apparent at 6 hours in both pancreatic cancer cell lines.
  • We are pleased with the results GP-2250 demonstrated, and the metabolic and transcriptional findings provide molecular targets for GP-2250.

Development of Cache Random Function to Enable Fast and Secure Data Access Between CPU Memories

Retrieved on: 
Wednesday, August 16, 2023
Technology, Mobile, Wireless, Security, Other Technology, Telecommunications, Blockchain, Software, Networks, Data Management, CASA, Communication, Computer security, USENIX, Ruhr University Bochum, Secure, Tohoku University, Research, Multimedia, Confidentiality, NTT Communications, ENC, Index, CPU, SCAR, Nippon Telegraph and Telephone, Research institute, NTT, Environment, Memory, Computer data storage

This research contributes to the realization of a highly secure CPU that prevents information leakage due to cache attacks.

Key Points: 
  • This research contributes to the realization of a highly secure CPU that prevents information leakage due to cache attacks.
  • View the full release here: https://www.businesswire.com/news/home/20230816297198/en/
    Figure 1: Conventional symmetric-key encryption model and cache randomization function specialized model (Photo: Business Wire)
    NTT designed and proposed a Secure Cache Randomization Function (SCARF) for randomization of cache index and formulated what type of function is suitable for randomizing of cache index[1] by providing design guidelines for randomization of cache function which formulated appropriate random function.
  • Current CPU introduces cache memory to reduce impact of delay required to transfer data between CPU memories by accelerating on subsequence references by placing used data near the CPU.
  • This value corresponds to the address in the cache used to allocate data from the main storage to the cache.

Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Merkel Cell Carcinoma (MCC)

Retrieved on: 
Thursday, June 29, 2023
Survival rate, STAT3, University, Glomus tumor, Bromodeoxyuridine, Merkel cell polyomavirus, Necrosis, Journal of Cancer Research and Clinical Oncology, Skin cancer, Quality of life, Ruhr University Bochum, University of Duisburg-Essen, AKT, Patient, Manuscript, Cancer, Flow cytometry, MCC, Apoptosis, MTT, Organ (biology), ST, Pharmaceutical industry, Vaccine, Panaveli, Angela Merkel, Erosion (morphology)

BERWYN, Pa., June 29, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the effectiveness of cancer treatments and quality of life for the patients that receive them, today announced the publication of positive preliminary data in a manuscript titled, “The effect of GP‑2250 on cultured virus‑negative Merkel cell carcinoma cells: preliminary results1,” in the peer-reviewed Journal of Cancer Research and Clinical Oncology.

Key Points: 
  • The objective of the preclinical study was to investigate the effects of GP-2250 on Merkel cell polyomavirus (MCPyV)-negative MCC cells.
  • Greg Bosch, Chairman and CEO of Panavance Therapeutics commented, “We are encouraged by these preclinical findings in this rare, aggressive form of skin cancer.
  • This study was able to show that GP-2250 has significant, dose-dependent cytotoxic effects on MCC cells as well as reduced cancer cell proliferation and migration.
  • GP-2250’s effects on cell viability, proliferation and migration were evaluated by means of MTT, BrdU, and scratch assays, respectively.

AdaptHealth Appoints Crispin Teufel as New Chief Executive Officer

Retrieved on: 
Tuesday, June 27, 2023
Diabetes, Medical Devices, Health, Health Insurance, Medical Supplies, Linde, Ruhr University Bochum, MBA, Certified Public Accountant, Teufel, Patient, PWC, Therapy, Commerce, Management, Economics

AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions, including home medical equipment, medical supplies and related services, announced today that its Board of Directors has named Crispin Teufel as Chief Executive Officer.

Key Points: 
  • AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions, including home medical equipment, medical supplies and related services, announced today that its Board of Directors has named Crispin Teufel as Chief Executive Officer.
  • Crispin Teufel, 47, has served as the Chief Executive Officer of Lincare Holdings Inc., a leading national provider of in-home respiratory care with over 700 locations in 48 states, since July 2017.
  • Previously, Mr. Teufel served as the Chief Financial Officer of Lincare from 2013 to 2019 and as a Finance Director for Linde Engineering in Germany from 2011 to 2013.
  • “We are quite pleased to be announcing the appointment of Crispin Teufel as the next Chief Executive Officer of AdaptHealth,” said Mr. Barasch.

Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis

Retrieved on: 
Wednesday, April 26, 2023
Filgotinib, Galapagos NV, CET, Week, Rheumatology, Doctor of Philosophy, Ruhr University Bochum, EMA, Euronext, MD, Patient, Internal medicine, European Medicines Agency, Safety, Pharmaceutical industry, Axial spondyloarthritis, Galápagos Islands, Immunology

Mechelen, Belgium; 26 April 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was randomized in OLINGUITO, the pivotal Phase 3 program of filgotinib in AxSpA.

Key Points: 
  • Mechelen, Belgium; 26 April 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was randomized in OLINGUITO, the pivotal Phase 3 program of filgotinib in AxSpA.
  • We look forward to advancing the OLINGUITO program and to working collaboratively with our clinical partners.”
    The OLINGUITO global Phase 3 program ( NCT05785611 ) consists of two randomized, placebo-controlled, double-blind, multi-center, parallel-group studies.
  • Each study will enroll approximately 238 patients who are randomized 1:1 to receive filgotinib 200mg or placebo once-daily.
  • The double-blind studies will be followed by an open-label treatment period in which all patients will receive filgotinib 200mg once-daily up to Week 52.